CN101155581A - Medicament and treatment for herpes simplex - Google Patents
Medicament and treatment for herpes simplex Download PDFInfo
- Publication number
- CN101155581A CN101155581A CNA2006800118064A CN200680011806A CN101155581A CN 101155581 A CN101155581 A CN 101155581A CN A2006800118064 A CNA2006800118064 A CN A2006800118064A CN 200680011806 A CN200680011806 A CN 200680011806A CN 101155581 A CN101155581 A CN 101155581A
- Authority
- CN
- China
- Prior art keywords
- herpes simplex
- medicine
- application
- infection
- alkaloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Abstract
A medicament for use in the treatment of viral infections, such as herpes simplex, that are transmitted anterogradely through the nervous system. Viruses, such as herpes simplex, may lie asymptomatically dormant or latent in nerve cell bodies of the CNS, but when reactivated, by whatever cause, are transported anterogradely along nerve cell axons to a surface of the body, where symptoms of the infection arise. A common form of herpes simplex infection lies dormant or latent in the trigeminal nerve ganglion until reactivated by stress, premenstrual tension or a range of other triggers. The herpes simplex virus (HSV) typically travels along trigeminal nerve axons to the lips, where it leads to symptoms such as cold sores. Herpes simplex infections may also take a more serious form in which the virus travels along nerve cells to the area of the eye socket. Here, HSV may cause symptoms such as ulceration of the cornea, with a potential serious effect on a patient's vision. The active ingredient of the medicament is an alkaloid such as colchicine, vinblastine, vincristine, a cytochalasin or derivaties thereof.
Description
The present invention relates to be used for the treatment of for example medicine of herpes simplex infections of the viral infection propagated by nervous system.The invention still further relates to the Therapeutic Method of these infection.
Many viral diseases are propagated by body along nervous system, and virus is utilized the elongated shape of most of neurocytes.Typical neurocyte comprises cyton and extended thus elongated aixs cylinder, and the length of aixs cylinder can be easily above 1/3rd meters.The structure that the aixs cylinder utilization is called microtubule transports out of chemical substance cyton (forward) and transports cyton (reverse) back.The aixs cylinder tip of each cyton can be connected with the cyton of one or more other neurocytes.
Therefore virus can be propagated from infection site along retrograde pathway along one or more aixs cylinders, arrives central nervous system (CNS), spinal cord and brain until them.
Virus for example herpes simplex virus can lie dormant or latent in the neurosome of CNS asymptomatically, but when being activated by any reason, forward is transported to body surface along the neurocyte aixs cylinder, occurs infection symptoms here.Common form of herpes simplex infection lies dormant or hide in neuroganglion until by stress, perhaps many other triggering factors of premenstrual tension activate.Herpes simplex virus (HSV) generally marches to each position such as eyes, nose, genitals or the most common lip of body along neural axon, cause symptom such as herpes labialis here.Herpes simplex infection also may be taked more serious form, and wherein virus marches to the eye socket district along neurocyte.At this place, HSV may cause such as symptoms such as corneal ulcer, patient's vision had possibility seriously influence.
Estimation has herpes simplex antibody up to 95% uk population, therefore thinks that they have infected the asymptomatic HSV that hides.Think that classical Vector of infection touches propagation for the lipped joint by relatives, before usually occurring in five years old.Also do not develop the method for avoiding it, because asymptomatic carrier still can infect other people.
The treatment that preferably is used at present herpes simplex infection is a medicine, for example the acyclovir that duplicates of viral interference.Be used for herpes labialis, it is as the topical cream administration, and is used for corneal ulcer, and typical prescription is that acyclovir is administered five times as ointment every day.In each case, acyclovir (or equivalent) is in case only administration when the HSV activity to be ready recurring (for example, acyclovir cold sore creams typically only " twinge " advance notice patient will have administration when just sending out herpes labialis in a single day).Preferably will be before HSV arrives body surface and begins to cause irritating or deleterious symptom, to slow down or stop HSV.Yet for chronic situation, possible every day secondary 400mg the doses over long periods oral administration.
Although main the description about being used for the treatment of the medicine that the human virus infects among the application, closely similar consideration is applicable to that also animal virus infects.What except as otherwise noted, all related to the people is interpreted as referring to equally animal.
Therefore, the purpose of this invention is to provide the medicine for treating viral infections that treatment is forward propagated by nervous system.The Therapeutic Method that these infection are provided also is a purpose of the present invention.
According to a first aspect of the invention, provide alkaloid or griseofulvin to be used for the treatment of forward application in the neural medicine for treating viral infections of propagating in production.
Advantageously, described alkaloid comprises antimitotic alkaloid.
Described alkaloid can comprise colchicine, vincaleucoblastine, vincristine, cytochalasin or derivatives thereof.
In preferred embodiments, the viral infection that treat comprises herpes infection, for example herpes simplex infection.
Preferably, described medicine is the form of Orally-administrable.
Advantageously, described medicine can be with the form administration of tablet, capsule, powder or granule.
Perhaps, described medicine comprises drinkable fluid composition.
But described medicine can comprise topical application of compositions.
Therefore, described medicine can comprise emulsifiable paste, ointment, ointment (salve), eye drop, nasal spray etc.
But described medicine can comprise the fluid composition of injectable or infusion.
According to a second aspect of the invention, be provided for treating the method for herpes simplex infection, it comprises and gives to disturb or to block the step that aixs cylinder is forward propagated the material of (transport).
Preferably, described method is included in the step that gives described material before infection symptoms shows effect.
Perhaps, described method comprises the preventative step that gives described material.
Described method preferably includes the step that comprises alkaloidal compositions, and described alkaloid advantageously is antimitotic alkaloid, for example colchicine, vincaleucoblastine or vincristine or griseofulvin.
Now embodiment of the present invention will be described more specifically by way of example.
First example relates to the patient with herpes labialis history, and this herpes labialis is caused by known trigger.For example, it may be the form that stress event is for example taken an examination.Another common triggering factors is because other infection (for example catch a cold, thereby gain the name " cold sore ") causes weakened immune system.The herpes labialis that some women suffer from regular outbreak is as through preceding symptom.Although for the definite triggering factors difference of each patient, they/they may recognize they/they face the situation of risk of relapse.
In the treatment of prior art, when herpes labialis had formed maybe when the primary stage that detects its formation (for example sensation of pricking of skin), local application contained the acyclovir ointment of 5 w/w %, and every day five times nearly is until cold sores subside.The course of disease persistent period may shorten well as a result, but the patient still has the herpes labialis of suffering from indecency and possible pain in several days.
In embodying treatment of the present invention, preference is as the form orally give colchicine with tablet or capsule.When the patient recognizes that some trigger events that may cause his or she generation herpes labialis have taken place or when being about to take place, replaces waiting for that herpes labialis occurs, the patient takes a slice or several the tablets that contain colchicine.
Perhaps, he or she can directly be applied to topical cream the possible position of herpes labialis, usually in lip week.Described emulsifiable paste comprises colchicine and conventional excipient and the promotion colchicine of choosing wantonly and sees through the reagent that patient skin absorbs.Think the trigeminal ganglion reverse osmosis of depots of the herpes simplex virus that colchicine is then hidden to conduct along neural axon.If HSV is activated, it will this stage to the skin surface forward transfer, but think that colchicine slows down even stops it to advance along aixs cylinder.If HSV does not arrive skin surface, then will not cause herpes labialis.
Second example relates to suffers from the ophthalmic or the patient of herpes simplex infection history near the eyes.These can cause corneal ulcer and to the temporary transient or nonvolatil injury of patient's vision.In addition, these infect that the HSV normally hide is activated by some triggering factors that can recognize and along the result of neural axon direct motion in trigeminal ganglion.
The treatment of prior art is that this moment, patient's vision may be dangerous to ophthalmic or the performance reaction of symptom near the eyes.The acyclovir (every day five times) that gives ointment is until ulcer healing.
In embodying treatment of the present invention, before outbreak, regularly or give the colchicine of tablet form when recognizing trigger event.Perhaps, once noticing that possible trigger event uses ointment or the eye drop that contains colchicine solution to patient's eyes.About first example, colchicine along aixs cylinder to the trigeminal ganglion reverse osmosis and disturb or stop HSV to advance to eyes.Almost do not have or do not have HSV to arrive eyes, prevent or significantly reduced the formation of ulcer.Any ulcer that the treatment of traditional acyclovir ointment can be used for still taking place, if but since these ulcer to can not show a candle to situation about not doing so serious, therefore eliminate the treatment time-histories that they will need much shorter.
Claims (12)
1. alkaloid or griseofulvin are used for the treatment of forward application in the neural medicine for treating viral infections of propagating in production.
2. the application in producing medicine of claim 1, wherein said alkaloid comprises colchicine, vincaleucoblastine, vincristine, cytochalasin or derivatives thereof.
3. the application of the alkaloid of claim 1 or claim 2 in producing medicine, the described viral infection that wherein will treat comprises herpes infection, for example herpes simplex infection.
4. the application of each of aforementioned claim, wherein said medicine are the form of Orally-administrable.
5. the application of claim 4, wherein said medicine can be with the form administration of tablet, capsule, powder or granule.
6. the application of claim 4, wherein said medicine comprises drinkable fluid composition.
7. the application of each of claim 1 to 3, but wherein said medicine comprises topical application of compositions.
8. the application of each of claim 1 to 3, but wherein said medicine comprises the fluid composition of injectable or infusion.
9. the Therapeutic Method of herpes simplex infection, it comprises the step that gives to disturb or to block the material that aixs cylinder forward propagates.
10. the method for claim 9, it is included in the step that gives described material before the infection symptoms outbreak.
11. the method for claim 9, it comprises the preventative step that gives described material.
12. the method for claim 9, it comprises the step that comprises alkaloidal compositions, and described alkaloid advantageously is antimitotic alkaloid, for example colchicine, vincaleucoblastine or vincristine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505076.0 | 2005-03-11 | ||
| GBGB0505076.0A GB0505076D0 (en) | 2005-03-11 | 2005-03-11 | Medicament and treatment for herpes simplex and other infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101155581A true CN101155581A (en) | 2008-04-02 |
Family
ID=34508938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800118064A Pending CN101155581A (en) | 2005-03-11 | 2006-03-10 | Medicament and treatment for herpes simplex |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1861088A1 (en) |
| JP (1) | JP2008543730A (en) |
| CN (1) | CN101155581A (en) |
| GB (1) | GB0505076D0 (en) |
| WO (1) | WO2006095178A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815179D0 (en) * | 2008-08-20 | 2008-09-24 | Sharma Anant | Medication and treatment for infection |
| GB201015305D0 (en) * | 2010-09-14 | 2010-10-27 | Ucl Business Plc | Methods, compounds and compositions relating to activating a latent virus |
| EP3073824A4 (en) * | 2013-11-25 | 2017-10-25 | Saint Louis University | Inhibitors of hsv nucleotidyl transferases and uses therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994388A (en) * | 1997-03-18 | 1999-11-30 | The Children's Medical Center Corporation | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis |
-
2005
- 2005-03-11 GB GBGB0505076.0A patent/GB0505076D0/en not_active Ceased
-
2006
- 2006-03-10 CN CNA2006800118064A patent/CN101155581A/en active Pending
- 2006-03-10 EP EP06726355A patent/EP1861088A1/en not_active Withdrawn
- 2006-03-10 JP JP2008500267A patent/JP2008543730A/en active Pending
- 2006-03-10 WO PCT/GB2006/000845 patent/WO2006095178A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006095178A1 (en) | 2006-09-14 |
| JP2008543730A (en) | 2008-12-04 |
| GB0505076D0 (en) | 2005-04-20 |
| EP1861088A1 (en) | 2007-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raborn et al. | Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study | |
| EP3666258B1 (en) | Method of treating prader-willi syndrome | |
| US20200101067A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| US9561249B2 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| Priya et al. | Intralesional vitamin D3 in recalcitrant palmoplantar and periungual warts: a prospective, observational study | |
| RU2443439C2 (en) | Method of treating lichen acuminatus | |
| CN101155581A (en) | Medicament and treatment for herpes simplex | |
| EP0906111B1 (en) | Composition and method for treating herpes simplex | |
| Kalogjera et al. | Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats | |
| KR101352238B1 (en) | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infecton | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| RU2358744C1 (en) | Onychomycosis therapy | |
| Shingadiya et al. | Ayurvedic Management of chronic Vitiligo (Shvitra): A case study | |
| DE19634537C2 (en) | Use of a drug containing histaglobin for application to a mucous membrane | |
| Bedford | A REVIEW of COVID-19 DIAGNOSIS, DIAGNOSTIC TESTING AND TREATMENT | |
| US20170360720A1 (en) | Method to supplement human immune system in suppressing hsv symptoms | |
| WO2003097061A1 (en) | External preparation for allergic diseases | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN100496492C (en) | Medendazole new formulation for treating chronic nasosinusitis | |
| Shinde et al. | MANAGEMENT OF PSORIASIS: A COMPARATIVE CLINICAL STUDY OF STANDARD AYURVEDA & ALLOPATHIC PROTOCOLS | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| Imafuku et al. | Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial | |
| EP3013330B1 (en) | Anti-viral compound and composition | |
| Verma et al. | COVID-19: Clinical management with immunomodulator therapy | |
| Yella et al. | ACEBROPHYLLINE INDUCED FIXED DRUG ERUPTIONS: A CASE REPORT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080402 |